Detection Rate of Serrated Adenomas in Screening Colonoscopy

Detection Rate of Serrated Adenomas in the Screening Colonoscopy Population

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT03442270

Enrollment

276

Registered

2018-02-22

Start date

2018-03-20

Completion date

2018-11-07

Last updated

2019-06-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy Patients Undergoing Screening Colonoscopy

Keywords

Serrated Adenoma, Colonoscopy

Brief summary

An observational prospective will be conducted to determine the detection rate of serrated adenoma during screening colonoscopy at our institution. Additionally, the variability of serrated adenoma detection among endoscopists will be evaluated and the characteristics of serrated adenomas will be described.

Detailed description

Colonoscopy screening is a preventative measure for colorectal carcinoma (CRC), a highly malignant and dangerous cancer. Extensive research on the adenoma detection rate has provided national standards and quality metrics to help assess competence of endoscopists. Currently, there are no standards established for serrated adenomas. The proposed study would be conducted at Good Samaritan Hospital (GSH) and TriHealth Surgery Center West. This is an observational study and does not involve any patient interventions. However, because patient healthcare data will be collected for research, informed consent will be obtained shortly before the procedure. The main study objective is to determine the detection rate of serrated adenoma during screening colonoscopy at our institution. Additionally, the variability of serrated adenoma detection among endoscopists will be evaluated and the characteristics of serrated adenomas will be described.

Interventions

OTHERNo Intervention

This is an observational study, so standard of care will be followed.

Study design

Observational model

OTHER

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Inclusion criteria

* Males and females

Exclusion criteria

* First degree relative (patient's parent, sibling or child) diagnosed with colorectal carcinoma at age of 59 or under * New onset of iron deficiency anemia (within past 3 months) * Abnormal imaging of colon within past 3 months * Inadequate visualization reported by endoscopist * Pregnant women

Design outcomes

Primary

Measure	Time frame	Description
Serrated Adenoma	March 2018 to October 2018	Prevalence of Serrated Adenoma

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026